Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Ochre Bio's logo with large white surrounding boarder

Ochre Bio develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic diseases. Ochre employs spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes, and develops combination therapies that are tested in donor livers kept alive outside of the body. Their scientific roots can be traced back over 15 years, leading liver genomics research and experience in bringing advanced therapies to market.

Elodie Siney, the BioEscalator's Marketing and Events Manager, talked with Ochre Bio’s CEO, Jack O’Meara, and CSO, Quin Wills, to learn more about the company’s work on developing genomic medicines to rejuvenate donors' livers before transplant. They discussed the pair’s backstories, how the company came to fruition and what the future looks like for Ochre Bio. Jack and Quin also gave their advice on setting up a new business.

Read the video transcript here

Elodie also spoke with Raphael Castellan, an Early Career Scientist (Target Validation) at Ochre Bio, on how he moved from academia to biotech.


Read the video transcript here


To view Iceland's Eurovision entrants as referenced in 'jumpers to jackets' click here

Jack O'Meara - CEO

Jack is a biomedical engineer with a background in bringing new health technologies to market. Jack helped get one of the first blockbuster gene therapies through FDA approval.

Quin Wills - CSO

Quin is an MD and computational biologist. He founded his first liver drug company 15 years ago, co-steered Oxford's single-cell genomics consortium, and founded the Cellular and Systems Genomics department for a leading biopharma.

Raphael Castellan - Early Career Scientist (Target Validation)

Raphael is a life scientist with 8 years of academic research experience, including 2 in data analysis, specialising in muscular (cardiac and skeletal) pathophysiology. He joined Ochre Bio's Target Validation team in January 2021 as an early career scientist.

Click here to visit Ochre Bio's website

Click here to see Ochre Bio's interview with China Global Television Network (CGTN)